// App-Quantinova.ai

: Ibrutinib Plus Obinutuzumab and Venetoclax in Relapsed/Refractory Mantle Cells Lymphoma Patients, Results of the OASIS Phase I Clinical Trial

Researchers

Presenter

  • Steven Le Gouill

Principal Investigators

  • Franck Morschhauser

  • Krimo Bouabdallah

  • Guillaume Cartron

  • Rene-Olivier Casasnovas

  • Noel-Jean Milpied

  • Thomas Gastinne

  • Andrew John Davies

  • Charles Herbaux

  • David Chiron

  • Mary Callanan

  • Simon Rule

Medical Centers

  • CRCINA, INSERM, CNRS, Angers University and Nantes University, Nantes, France

  • Hopital Claude Huriez, Lille, France

  • Hematology, University Hospital of Bordeaux, Pessac, France

  • Department of Gastroenterology, CHU de Montpellier, Montpellier, France

  • Department of Urology, University Hospital, Dijon, France

  • Hopital Haut Leveque - Pessac, Pessac, FRA

  • Pediatric Hematology, Nantes University Hospital, Nantes, France

  • Cancer Sciences, University of Southampton, Southampton, United Kingdom

  • Service des Maladies du Sang, CHU Lille, Lille, France

  • Hematologie Clinique, Dijon University Hospital, Dijon, France

  • Department of Haematology, Plymouth University Medical School, Plymouth, United Kingdom

Locations

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Venetoclax

  • Ibrutinib

Outcome

  • N/A

Study Design

  • Randomized

  • Multicenteric

Phase

  • I

Study Id's

  • NCT02558816

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved